Preventing primary liver cancer: The HBV vaccination project in the Gambia (West Africa)

Environmental Health: A Global Access Science Source

Volumn 10, Issue SUPPL. 1, 2011, Pages

  Montesano, Ruggero ^a  

^a NONE   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

AFLATOXIN B1; HEPATITIS B SURFACE ANTIBODY; HEPATITIS B SURFACE ANTIGEN; HEPATITIS B VACCINE;

CANCER; HEALTH EDUCATION; HEPATITIS; INFECTIOUS DISEASE; PLASMA; PUBLIC HEALTH; SPATIOTEMPORAL ANALYSIS; VACCINATION; VACCINE;

CANCER INCIDENCE; CANCER PREVENTION; CANCER RISK; CONFERENCE PAPER; DRUG EFFICACY; DRUG SAFETY; GAMBIA; HEALTH PROGRAM; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; LIVER CANCER; LUNG CARCINOGENESIS; PREVALENCE; PRIORITY JOURNAL; SOUTHEAST ASIA; VACCINATION; VIRUS TRANSMISSION; ARTICLE; LIVER CELL CARCINOMA; LIVER TUMOR; MOLECULAR EPIDEMIOLOGY; PHYSIOLOGY; RISK FACTOR;

ASIA; GAMBIA;

HEPATITIS B VIRUS;

CARCINOMA, HEPATOCELLULAR; GAMBIA; HEPATITIS B; HEPATITIS B VACCINES; HEPATITIS B VIRUS; HUMANS; LIVER NEOPLASMS; MOLECULAR EPIDEMIOLOGY; RISK FACTORS;

EID: 79953833641     PISSN: None     EISSN: 1476069X     Source Type: Journal    
DOI: 10.1186/1476-069X-10-S1-S6     Document Type: Conference Paper

References (16)

1. GLOBOCAN 2008, Cancer Incidence and Mortality Worldwide: IARC CancerBase No. 10 [Internet]. J Ferlay HR Shin F Bray D Forman C Mathers DM Parkin, International Agency for Research on Cancer: Lyon, France 2010
2. Part I: Cancer in indigenous Africans - burden, distribution, and trends. DM Parkin F Sitas M Chirenje L Stein R Abratt H Wabinga, Lancet Oncology 2008 9 683 692 10.1016/S1470-2045(08)70175-X 18598933 (Pubitemid 351878054)
3. Part II: Cancer in indigenous Africans - causes and control. F Sitas DM Parkin M Chirenje L Stein R Abratt H Wabinga, Lancet Oncology 2008 9 786 795 10.1016/S1470-2045(08)70198-0 18672214 (Pubitemid 352038317)
4. IARC Monographs on the Evaluation of Carcinogenic Risks to Humans. International Agency for Research on Cancer, Hepatitis Viruses Lyon: International Agency for Research on Cancer 1994 59 45
5. IARC Monographs on the Evaluation of Carcinogenic Risks to Humans. International Agency for Research on Cancer, Hepatitis Viruses Lyon: International Agency for Research on Cancer 1994 59 165
6. IARC Monographs on the Evaluation of Carcinogenic Risks to Humans. International Agency for Research on Cancer, Some Traditional Herbal Medicines, Some Mycotoxins, Naphthalene and Styrene Lyon: International Agency for Research on Cancer 2002 82 171
7. Prevention and control of hepatitis B in China. Z Sun L Ming X Zhu J Lu, J Med Virol 2002 67 447 450 10.1002/jmv.10094 12116043
8. Hepatocellular carcinoma and HBV: a prospective study of 22,707 men in Taiwan. RP Beasly LY Hwang CC Lin CS Chien, The Lancet 1981 2 1129 1133 10.1016/S0140-6736(81)90585-7
9. The Gambia Hepatitis Intervention Study. The Gambia Hepatitis Study Group. GHIS, Cancer Res 1987 47 5782 5787 2822233
10. 20 years into the Gambia Hepatitis Intervention Study: assessment of initial hypothesis and prospects for evaluation of protective effectiveness against liver cancer. S Viviani P Carrieri E Bah AJ Hall GD Kirk M Mendy R Montesano A Plymoth O Sam M Van der Sande H Whittle P Hainaut The Gambia Hepatitis Intervention Study, Cancer Epidemiol Biomarkers Prev 2008 17 3216 3223 10.1158/1055-9965.EPI-08-0303 18990765
11. Decreased incidence of hepatocellular carcinoma in hepatitis B vaccinees: a 20-year follow-up study. M-H Chang S-L You C-J Chen C-J Liu C-M Lee S-M Lin H-C Chu T-C Wu S-S Yang H-S Kuo D-S Chen Taiwan Hepatoma Study Group, JNCI 2009 101 1348 1355 19759364
12. A mathematical model to estimate global hepatitis B disease burden and vaccination impact. ST Goldstein F Zhou SC Hadler BP Bell EE Mast HS Margolis, Int J Epidemiol 2005 34 1329 1339 10.1093/ije/dyi206 16249217 (Pubitemid 41819540)
13. Molecular epidemiology of human liver cancer: insights into etiology, pathogenesis and prevention from The Gambia, West Africa. GD Kirk E Bah R Montesano, Carcinogenesis 2006 27 2070 2082 10.1093/carcin/bgl060 16679307 (Pubitemid 44530582)
14. 249(ser) TP53 mutation in plasma DNA, hepatitis B viral infection, and risk of hepatocellular carcinoma. GD Kirk OA Lesi M Mendy K Szymãska H Whittle JJ Goedert P Hainaut R Montesano, Oncogene 2005 24 5858 5867 10.1038/sj.onc.1208732 16007211 (Pubitemid 43080077)
15. Mycotoxins and human disease: a largely ignored global health issue. CP Wild YY Gong, Carcinogenesis 2009 31 71 82 10.1093/carcin/bgp264 19875698
16. Hepatitis B vaccination in infancy in The Gambia: protection against carriage at 9 years of age. S Viviani A Jack AJ Hall N Maine M Mendy R Montesano HC Whittle, Vaccine 1999 17 2946 2950 10.1016/S0264-410X(99)00178-4 10462228 (Pubitemid 29366973)